News|Articles|September 30, 2009
Survey Reveals Biotech Professionals' Attitude Toward New Business Models
A recent, free report, reveals biotech professionals' evaluations of potential business model alternatives for the future.
Advertisement
The following table shows the results of respondents' answers to the question: Given that some of the more traditional avenues to drug development could be facing problems, from the list below please indicate any change in your company’s stance or relative interest in using each drug development model/partner. As you will see from the following responses, choices varied greatly.
Source: Industry Standard Research, 2009.
You can view the full report
For more information on biotech, please see:
More Data Points:
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Trials Need More Than AI: Why Operational Trial Infrastructure Matters
2
ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap
3
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
4
ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial
5